Matrubials

Matrubials is a pioneering anti-infectives company dedicated to harnessing the therapeutic potential of human milk peptides to combat antimicrobial resistance and address contemporary diseases. The escalating global incidence of severe bacterial infections, coupled with a diminishing pipeline of effective treatments, poses a significant burden on healthcare systems and economies worldwide. Leveraging the evolutionary advantages inherent in milk, the primary source of nourishment and protection for newborns, Matrubials is developing innovative solutions to address both nutritive and protective challenges. The anti-pathogenic molecules found in milk are being developed into therapeutics targeting diseases across all age groups. Their initial focus is on bacterial vaginosis, a bacterial dysbiosis-related inflammation characterized by recurrent infections, disruption of homeostasis, and long-term clinical complications in women of reproductive age, including preterm births, fertility issues, and increased susceptibility to STDs. The next critical step involves evaluating rapidly acting and selective candidate peptides in pre-clinical host impact and early safety studies, which will inform clinical and portfolio development for topical applications.